Synthesized peptide derived from human PIK3CA H1047R AA range: 1000-1068

The antibody can specifically recognize the h1047r mutation of human PIK3CA protein, and does not react with wild-type PIK3CA protein.

PIK3CA

5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha;5-bisphosphate 3-kinase catalytic subunit alpha isoform;caPI3K;CLOVE;CWS5;MCAP;MCM;MCMTC;MGC142161;MGC142163;p110 alpha;p110alpha;Phosphatidylinositol 3 kinase catalytic alpha polypeptide;Phosphatidylinositol 3 kinase catalytic 110 KD alpha;Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha;Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform;Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha;Phosphatidylinositol-4;Phosphoinositide 3 kinase catalytic alpha polypeptide;PI 3 Kinase catalytic subunit alpha;PI3 kinase p110 subunit alpha;PI3-kinase subunit alpha;PI3K;PI3K-alpha;PI3KC A;PIK3C A;Pik3ca;PK3CA;PK3CA_HUMAN;PtdIns 3 kinase p110;PtdIns-3-kinase subunit alpha;PtdIns-3-kinase subunit p110-alpha;Serine/threonine protein kinase PIK3CA

5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha ;
5-bisphosphate 3-kinase catalytic subunit alpha isoform ;
caPI3K ;
CLOVE ;
CWS5 ;
MCAP ;
MCM ;
MCMTC ;
MGC142161 ;
MGC142163 ;
p110 alpha ;
p110alpha ;
Phosphatidylinositol 3 kinase catalytic alpha polypeptide ;
Phosphatidylinositol 3 kinase catalytic 110 KD alpha ;
Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha ;
Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform ;
Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha ;
Phosphatidylinositol-4 ;
Phosphoinositide 3 kinase catalytic alpha polypeptide ;
PI 3 Kinase catalytic subunit alpha ;
PI3 kinase p110 subunit alpha ;
PI3-kinase subunit alpha ;
PI3K ;
PI3K-alpha ;
PI3KC A ;
PIK3C A ;
Pik3ca ;
PK3CA ;
PK3CA_HUMAN ;
PtdIns 3 kinase p110 ;
PtdIns-3-kinase subunit alpha ;
PtdIns-3-kinase subunit p110-alpha ;
Serine/threonine protein kinase PIK3CA

Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016],

Catalytic activity:ATP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate.,Disease:Defects in PIK3CA are associated with breast cancer [MIM:114480].,Disease:Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500].,Disease:Defects in PIK3CA are associated with ovarian cancer [MIM:167000]. Ovarian cancer is the leading cause of death from gynecologic malignancy. It is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases. These typical features relate to the biology of the disease, which is a principal determinant of outcome.,Disease:Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550].,Disease:PI3KCA mutations affecting exons 9 and 20 display gender-and tissue-specific patterns, thus suggesting that the different amino acid changes could exert distinct functional effects on the oncogenic properties of this enzyme. Furthermore, sexual dimorphisms and tissue specific factors might directly or indirectly influence the occurrence of PI3KCA cancer alleles.,Function:Phosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2.,similarity:Belongs to the PI3/PI4-kinase family.,similarity:Contains 1 C2 domain.,similarity:Contains 1 PI3K/PI4K domain.,subunit:Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunit. Binds to IRS1 in nuclear extracts. Interacts with RUFY3.,

Cytoplasmic

Gastric adenocarcinoma with PIK3CA H1047R protein expression

>>Inositol phosphate metabolism ;
>>Metabolic pathways ;
>>EGFR tyrosine kinase inhibitor resistance ;
>>Endocrine resistance ;
>>Platinum drug resistance ;
>>ErbB signaling pathway ;
>>Ras signaling pathway ;
>>Rap1 signaling pathway ;
>>cAMP signaling pathway ;
>>Chemokine signaling pathway ;
>>HIF-1 signaling pathway ;
>>FoxO signaling pathway ;
>>Phosphatidylinositol signaling system ;
>>Sphingolipid signaling pathway ;
>>Phospholipase D signaling pathway ;
>>Autophagy - animal ;
>>mTOR signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>AMPK signaling pathway ;
>>Apoptosis ;
>>Longevity regulating pathway ;
>>Longevity regulating pathway - multiple species ;
>>Cellular senescence ;
>>Axon guidance ;
>>VEGF signaling pathway ;
>>Osteoclast differentiation ;
>>Focal adhesion ;
>>Signaling pathways regulating pluripotency of stem cells ;
>>Platelet activation ;
>>Neutrophil extracellular trap formation ;
>>Toll-like receptor signaling pathway ;
>>C-type lectin receptor signaling pathway ;
>>JAK-STAT signaling pathway ;
>>Natural killer cell mediated cytotoxicity ;
>>T cell receptor signaling pathway ;
>>B cell receptor signaling pathway ;
>>Fc epsilon RI signaling pathway ;
>>Fc gamma R-mediated phagocytosis ;
>>TNF signaling pathway ;
>>Leukocyte transendothelial migration ;
>>Neurotrophin signaling pathway ;
>>Cholinergic synapse ;
>>Inflammatory mediator regulation of TRP channels ;
>>Regulation of actin cytoskeleton ;
>>Insulin signaling pathway ;
>>Progesterone-mediated oocyte maturation ;
>>Estrogen signaling pathway ;
>>Prolactin signaling pathway ;
>>Thyroid hormone signaling pathway ;
>>Regulation of lipolysis in adipocytes ;
>>Relaxin signaling pathway ;
>>GnRH secretion ;
>>Type II diabetes mellitus ;
>>Insulin resistance ;
>>Non-alcoholic fatty liver disease ;
>>AGE-RAGE signaling pathway in diabetic complications ;
>>Growth hormone synthesis, secretion and action ;
>>Aldosterone-regulated sodium reabsorption ;
>>Carbohydrate digestion and absorption ;
>>Alzheimer disease ;
>>Spinocerebellar ataxia ;
>>Prion disease ;
>>Bacterial invasion of epithelial cells ;
>>Shigellosis ;
>>Salmonella infection ;
>>Yersinia infection ;
>>Chagas disease ;
>>Amoebiasis ;
>>Hepatitis C ;
>>Hepatitis B ;
>>Measles ;
>>Human cytomegalovirus infection ;
>>Influenza A ;
>>Human papillomavirus infection ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Herpes simplex virus 1 infection ;
>>Epstein-Barr virus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Coronavirus disease - COVID-19 ;
>>Pathways in cancer ;
>>Viral carcinogenesis ;
>>Proteoglycans in cancer ;
>>MicroRNAs in cancer ;
>>Chemical carcinogenesis - receptor activation ;
>>Chemical carcinogenesis - reactive oxygen species ;
>>Colorectal cancer ;
>>Renal cell carcinoma ;
>>Pancreatic cancer ;
>>Endometrial cancer ;
>>Glioma ;
>>Prostate cancer ;
>>Melanoma ;
>>Chronic myeloid leukemia ;
>>Acute myeloid leukemia ;
>>Small cell lung cancer ;
>>Non-small cell lung cancer ;
>>Breast cancer ;
>>Hepatocellular carcinoma ;
>>Gastric cancer ;
>>Central carbon metabolism in cancer ;
>>Choline metabolism in cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Diabetic cardiomyopathy ;
>>Lipid and atherosclerosis ;
>>Fluid shear stress and atherosclerosis